At $575 million raised and a $10.1 billion valuation, Whoop’s Series G is a landmark for performance wearables. That seven elite athletes — from Ronaldo to van der Poel — put equity behind it says as much about the platform as any financial metric.
Seven elite athletes representing five different sports have invested in Whoop’s latest funding round, joining sovereign funds, hospital networks and a major medtech group in a $575 million Series G that values the Boston-based wearable and health intelligence platform at $10.1 billion.
The breadth and sport-by-sport diversity of the athlete investor pool sets this round apart from the celebrity-backed deals that have become routine in consumer tech – and positions it squarely within the emerging pattern of athletes deploying capital into platforms they rely on professionally.
The athlete investors are soccer players Cristiano Ronaldo and Virgil van Dijk, basketball players LeBron James and Reggie Miller, golfers Rory McIlroy and Shane Lowry, and cyclist Mathieu van der Poel. Musician Niall Horan also participated as an individual investor.
The institutional layer: Abbott’s entry signals a healthcare boundary shift
Beyond the athlete names, the composition of the institutional investor pool carries its own strategic signal. Collaborative Fund led the round, with sovereign capital from the Qatar Investment Authority (QIA) and Mubadala Investment Company, and venture participation from Macquarie Capital, Glade Brook, B-Flexion, IVP, Foundry, Accomplice, Affinity Partners, Promus Ventures and Bullhound Capital.
But the most consequential new entrant is Abbott – the diversified medtech group spanning diagnostics, medical devices, nutrition and generics – which joins as a strategic investor alongside Mayo Clinic, one of the US’s leading nonprofit hospital networks.
Abbott’s participation is not passive financial exposure. The medtech giant brings regulatory experience and a track record in clinical health monitoring at a moment when Whoop is managing an active dispute with US federal authorities.
In July 2025, the US Food and Drug Administration (FDA) issued the company a warning letter, asserting that its blood pressure insights (BPI) feature met the legal definition of a medical device under the Federal Food, Drug, and Cosmetic Act. Founder and CEO Will Ahmed publicly rejected that conclusion, arguing that the feature is a wellness tool rather than a diagnostic instrument. No resolution has been reported.
Abbott’s entry carries its own implicit answer to the regulatory question: a medtech group whose portfolio spans clinical diagnostics and medical devices does not make strategic investments in products it considers mere wellness gadgets. Whatever the FDA ultimately rules, Whoop will navigate that outcome with a partner whose experience covers the full device approval landscape – and whose presence on the cap table reframes the regulatory risk as a transition to manage rather than a threat to contain.
Business fundamentals underpin the valuation
The $10.1 billion figure – nearly triple the $3.6 billion Whoop achieved in its August 2021 Series F – is anchored by substantive operating metrics.
- Bookings grew 103 percent year over year in 2025, and the company closed the year at a $1.1 billion run rate, operating cash flow positive.
- Membership has passed 2.5 million globally, sustained by a subscription model in which the wearable hardware carries no upfront cost while members pay for access to artificial intelligence (AI)-driven recovery, sleep and cardiovascular strain insights drawn from more than 24 billion hours of recorded physiological data.
- Total capital raised since the company’s founding in 2012 now exceeds $900 million.
- Over 600 roles are currently open as Whoop scales research and development and international operations across Europe, the Middle East, Latin America and Asia.
A sector still attracting capital despite a cyclical reset
The round arrives during a measured period for fitness tech investment broadly. Global venture funding to fitness and wellness startups reached approximately $5 billion in 2025, according to Crunchbase data – below the sector’s earlier peak, but sufficient to support several large transactions.
Finnish smart ring maker Oura closed more than $900 million in funding at an $11 billion valuation in October 2025, reinforcing sustained investor appetite for subscription-based health data platforms. The broader wearable tech market was valued at over $110 billion in 2024, with projections from industry analysis suggesting it could approach $400 billion by 2030.
Fresh capital will fund that international expansion, building on Whoop’s existing positions as title sponsor of the UCI Mountain Bike World Series, official partner of Ferrari’s Formula 1 program and the PGA Tour, and – announced last week – a new global agreement with Premier Padel.
“Our raise brings together the world’s most sophisticated investors, leading health institutions, and iconic global athletes behind the mission to unlock human performance and healthspan.”, Ahmed stated.
